Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • Wainzua

    - PMLiVE

    AstraZeneca’s Enhertu combination approved by FDA for HER2-positive breast cancer

    Around one in five breast cancer cases are HER2-positive

    - PMLiVE

    AstraZeneca’s Imfinzi receives FDA approval for gastric and gastro-oesophageal cancers

    In 2022, nearly one million new patients were diagnosed with gastric cancer

    - PMLiVE

    AstraZeneca announces $2bn investment in US manufacturing

    The new and expanded facilities will support production of rare disease drug treatments

    - PMLiVE

    AstraZeneca reports positive results from rare disease trial

    HES is a group of rare disorders characterised by persistently elevated levels of white blood cells

    - PMLiVE

    AstraZeneca reports positive results from phase 3 blood pressure trial

    The study demonstrated reduction in systolic blood pressure compared to placebo in patient with hypertension

    - PMLiVE

    AstraZeneca to invest $4.5bn in US manufacturing facility

    The investment will further support the company’s growing oncology pipeline

    - PMLiVE

    AstraZeneca announces agreement with US government to reduce medicine costs

    The pharma company is the latest to offer direct-to-consumer purchasing

    - PMLiVE

    Lilly’s early Alzheimer’s disease treatment approved in the EU

    Marketing authorisation follows positive late-stage trial results

    - PMLiVE

    AstraZeneca and Merck decision to disinvest in the UK is a ‘tragedy’ for British research and innovation

    Kate Shaw comments on the latest news about AstraZeneca and Merck's decision to hold planned investments in the UK

    Innovative Trials

    - PMLiVE

    AstraZeneca’s Imfinzi/Imjudo regimen recommended by NICE to treat liver cancer

    Approximately 6,600 people are diagnosed with liver cancer every year in the UK

    - PMLiVE

    Sanofi’s Sarclisa approved by EC to treat newly diagnosed multiple myeloma

    The drug is already approved in the EU across three other multiple myeloma indications

    - PMLiVE

    AstraZeneca’s Imfinzi granted FDA priority review to treat early-stage gastric cancer

    Gastric cancer is the fifth leading cause of cancer-related deaths globally

    Subscribe to our email news alerts

    Latest content

    Latest intelligence

    Quick links